MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Bevacizumab (Avastatin)

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable […]

Comments Off on Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Onco Targets and Therapy 2017 April [Link] Levin PA, Dowell JE Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players […]

Comments Off on Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link] Chia PL, Russell P, Scott AM, John T Abstract INTRODUCTION: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated […]

Comments Off on Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

Journal of the National Comprehensive Cancer Network 2016 July 14 [Link] Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins […]

Comments Off on NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients

Genomics Data 2016 June 20 [Link] Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G Abstract Malignant pleural mesothelioma (MPM) is a tumor originating in the mesothelium, the membrane lining the thoracic cavities, and is induced by exposure to asbestos. Australia suffers one of the world’s highest rates of MPM and the incidence […]

Comments Off on MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients

Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells

Oncogene 2016 June 27 [Epub ahead of print] [Link] Eguchi R, Nakano T, Wakabayashi I. Abstract Malignant mesothelioma is an aggressive tumor arising from the mesothelial cells of serous membranes and is associated with tumor angiogenesis, which is a prerequisite for tumor progression. Vascular endothelial growth factors (VEGFs) including VEGF-A have a crucial role in […]

Comments Off on Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Lancet 2015 December 21 [Epub ahead of print] [Link] Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup […]

Comments Off on Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed

Journal of Controlled Release 2015 October 18 [Epub ahead of print] [Link] Ando H, Kobayashi S, Abu Lila AS, Eldin NE, Kato C, Shimizu T, Ukawa M, Kawazoe K, Ishida T. Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer that proliferates in the pleural cavity. Pemetrexed (PMX) in combination with cisplatin is currently the […]

Comments Off on Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with […]

Comments Off on Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)